[EN] PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS<br/>[FR] PYRAZOLOPYRIMIDINES UTILISES COMME AGENTS ANTI-HEPATITE C
申请人:ARROW THERAPEUTICS LTD
公开号:WO2005047288A1
公开(公告)日:2005-05-26
Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R1 is C6-C10 aryl, 5- to 10- membered heteroary1, -(C1-C4 alkyl)-(C6-C10 aryl) or -(C1-C4 alkyl)-(5- to 10- membered heteroaryl); R2 is a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C6C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10membered heterocyclic ring; and X is -NR'-, -NR'-CO-NR''-, -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C1-C6 alkyl group and L represents a C1-C6 alkylene group, the aryl, heteroaryl, heterocyclyl. and carbocyclyl moieties in the R1 and R2 substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'CO2-R'', -CO2R'', -COR'''-NR'-CO-R''',-CONR'R'',SO2NR'R'',SO2R'''and -O-(CH2)n-R''' substituents, wherein n is from 0 to 4, each R’is the same or different and is hydrogen or C1-C6 alkyl, each R'' is the same or different and is hydrogen, C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R'''' is the same or different and is C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C1-C4 alkyl, C1-C4 hydroxyalkyl and C1-C4 haloalkyl groups.
式(I)的吡唑啉衍生物,或其药用可接受的盐,被发现对丙型肝炎感染具有活性,其中:R1为C6-C10芳基,5-到10-成员杂芳基,-(C1-C4烷基)-(C6-C10芳基)或-(C1-C4烷基)-(5-到10-成员杂芳基);R2为C6-C10芳基,C3-C6碳环烷基,5-到10-成员杂芳基或5-到10-成员杂环烷基基团,该基团可选择地与C6-C10芳基,C3-C6碳环烷基,5-到10-成员杂芳基或5-到10-成员杂环烷基环融合;X为-NR'-,-NR'-CO-NR''-,-NR'-L,或-NR'-CO-L-,其中R'和R''相同或不同,分别代表氢或C1-C6烷基,L代表C1-C6烷基基团,R1和R2取代基中的芳基,杂芳基,杂环烷基和碳环烷基基团未取代或通过1、2或3个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基、氰基、硝基、C6-C10芳基、C3-C6碳环烷基、5-到10-成员杂环烷基、5-到10-成员杂芳基、-NR'-CO2-R''、-CO2R''、-COR'''-NR'-CO-R'''、-CONR'R''、SO2NR'R''、SO2R'''和-O-(CH2)n-R'''取代。